Promising Penny Stocks To Keep An Eye On – October 19th

SCWorx, D. Boral ARC Acquisition I, and Alaunos Therapeutics are the three Penny stocks to watch today, according to MarketBeat’s stock screener tool. Penny stocks are shares of companies that trade at very low prices, typically outside major stock exchanges and often for less than $5 per share. They can offer significant growth potential but are generally highly volatile, less liquid, and riskier because they often involve smaller companies with limited financial information. These companies had the highest dollar trading volume of any Penny stocks within the last several days.

SCWorx (WORX)

SCWorx Corp. develops and markets health care information technology solutions and related services to improve healthcare processes and information flow within hospitals and other healthcare facilities in the United States. The company provides data content and services related to repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry.

Read Our Latest Research Report on WORX

D. Boral ARC Acquisition I (XLAB)

We are a blank check company incorporated on March 20, 2025 as a BVI business company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination.

Read Our Latest Research Report on XLAB

Alaunos Therapeutics (TCRT)

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.

Read Our Latest Research Report on TCRT

Recommended Stories